公开(公告)号：US20220226448A1

公开(公告)日：2022-07-21

申请号：US17595588

申请日：2020-05-22

Applicant: BAYLOR RESEARCH INSTITUTE

Inventor： Botond Z. IGYÁRTÓ ,  Qingtai SU

IPC: A61K39/00 ,  A61K39/39 ,  A61P35/00

Abstract: Methods and compositions using artificial antigen presenting cells in immunotherapy. The artificial antigen presenting cells comprise substrate particles bound to endogenous MHC-peptide complexes obtained from one or more cells. Methods include administering the artificial antigen presenting cells to a patient to activate antigen-specific T cells.

公开(公告)号：US20220175920A1

公开(公告)日：2022-06-09

申请号：US17598582

申请日：2020-03-26

Applicant: INSERM (Institut National de la Santé et de la Recherche Médicale) ,  Université Paris est Cretéil Val de Marne ,  Baylor Research Institute ,  Assistance Publique-Hôpitaux de Paris (APHP)

Inventor： Yves LEVY ,  Valentina CEGLIA ,  Sandra ZURAWSKI ,  Gerard ZURAWSKI

IPC: A61K39/395 ,  A61K39/385 ,  C07K14/705 ,  C07K16/28 ,  A61P31/18

Abstract: The disclosure relates to the field of CD40 activating proteins. More specifically, it is disclosed herein recombinant proteins with CD40 agonist antibodies or their antigen-binding fragments fused or linked to CD40 ligand. Also disclosed is the advantageous use of such CD40 activating proteins, in particular for inducing immune responses directed to delivered antigens such as viral or cancer antigens.

公开(公告)号：US20220152192A1

公开(公告)日：2022-05-19

申请号：US17454108

申请日：2021-11-09

Applicant: BAYLOR RESEARCH INSTITUTE

Inventor： SangKon OH ,  Dapeng LI

IPC: A61K39/145 ,  A61K47/68 ,  A61K51/10 ,  C07K16/28 ,  C07K14/005 ,  C07K14/195 ,  C07K14/37 ,  C07K14/405 ,  C07K14/435 ,  C12N5/0784 ,  C12N7/00

Abstract: The present invention includes compositions and methods for making and using anti DC-ASGPR antibodies that can, e.g., activate DCs and other cells.

公开(公告)号：US11267895B2

公开(公告)日：2022-03-08

申请号：US16946302

申请日：2020-06-15

Applicant: BAYLOR RESEARCH INSTITUTE

Inventor： Jacques F. Banchereau ,  Gerard Zurawski ,  Sandra Zurawski ,  SangKon Oh

IPC: C07K16/28 ,  C07K14/005 ,  A61K39/00

Abstract: The present invention includes compositions and methods for the expression, secretion and use of novel compositions for use as, e.g., vaccine and antigen delivery vectors, to delivery antigens to antigen presenting cells. In one embodiment, the vector is an anti-CD40 antibody, or fragments thereof, and one or more antigenic peptides linked to the anti-CD40 antibody or fragments thereof, including humanized antibodies.

公开(公告)号：US20220054609A1

公开(公告)日：2022-02-24

申请号：US17447607

申请日：2021-09-14

Applicant: BAYLOR RESEARCH INSTITUTE

Inventor： SangKon OH ,  Gerard ZURAWSKI

IPC: A61K39/00 ,  C07K16/28 ,  C07K14/46

Abstract: Methods and compositions for treating multiple sclerosis using dendritic cell anti-ASGPR antibodies fused to myelin basic protein or myelin oligodendrocyte glycoprotein are provided.

公开(公告)号：US11173202B2

公开(公告)日：2021-11-16

申请号：US16372832

申请日：2019-04-02

Applicant: BAYLOR RESEARCH INSTITUTE

Inventor： SangKon Oh ,  Dapeng Li

IPC: A61K39/145 ,  A61K47/68 ,  A61K51/10 ,  C07K16/28 ,  C07K14/005 ,  C07K14/195 ,  C07K14/37 ,  C07K14/405 ,  C07K14/435 ,  C12N5/0784 ,  C12N7/00 ,  A61K39/00

Abstract: The present invention includes compositions and methods for making and using anti DC-ASGPR antibodies that can, e.g., activate DCs and other cells.

公开(公告)号：US20210145784A1

公开(公告)日：2021-05-20

申请号：US16911195

申请日：2020-06-24

Applicant: Baylor Research Institute

Inventor： Charles R. ROE

IPC: A61K31/225 ,  A23L33/10 ,  A23L33/12 ,  A23L33/175 ,  A23K20/174 ,  A23K20/158 ,  A23K50/10 ,  A23K50/75 ,  A23K50/80 ,  A61K31/202 ,  A61K31/19 ,  A61K31/22 ,  A23L2/52 ,  A61K9/00 ,  A61K38/47 ,  A23L33/115 ,  A23L33/16

Abstract: A method for treating glycogen storage disease by administering an effective amount of a composition that includes ketogenic odd carbon fatty acids that ameliorate the symptoms of these diseases.

公开(公告)号：US20210139992A1

公开(公告)日：2021-05-13

申请号：US16492524

申请日：2018-03-09

Applicant: BAYLOR RESEARCH INSTITUTE

Inventor： Ajay GOEL ,  Daisuke IZUMI

IPC: C12Q1/6886

Abstract: Dysregulated expression of microRNAs (miRNAs) has emerged as a hallmark feature in human cancers. Aspects of the disclosure relate to methods for selecting optimal therapy for a patient from several alternative treatment options. A major clinical challenge in cancer treatment is to identify the subset of patients who will benefit from a therapeutic regimen, both in metastatic and adjuvant settings. The number of anti-cancer drugs and multi-drug combinations has increased substantially in the past decade, however, treatments continue to be applied empirically using a trial-and-error approach. Here methods and compositions are provided to determine the optimal treatment option for gastric cancer patients.

公开(公告)号：US20210024641A1

公开(公告)日：2021-01-28

申请号：US16946302

申请日：2020-06-15

Applicant: BAYLOR RESEARCH INSTITUTE

Inventor： Jacques F. Banchereau ,  Gerard Zurawski ,  Sandra Zurawski ,  SangKon Oh

IPC: C07K16/28 ,  C07K14/005

Abstract: The present invention includes compositions and methods for the expression, secretion and use of novel compositions for use as, e.g., vaccine and antigen delivery vectors, to delivery antigens to antigen presenting cells. In one embodiment, the vector is an anti-CD40 antibody, or fragments thereof, and one or more antigenic peptides linked to the anti-CD40 antibody or fragments thereof, including humanized antibodies.

公开(公告)号：US10722572B2

公开(公告)日：2020-07-28

申请号：US16708787

申请日：2019-12-10

Applicant: INSERM (Institut National de la Sante et de la Recherche Medicale) ,  Baylor Research Institute ,  Universite Paris Est Creteil Val De Marne ,  Assistance Publique Hopitaux de Paris

Inventor： Yves Levy ,  Gerard Zurawski ,  Sandra Zurawski ,  Anne-Laure Flamar

IPC: C07K16/28 ,  A61K39/00 ,  A61K39/395 ,  A61K39/12 ,  A61K39/21 ,  C07K14/005 ,  C12N7/00 ,  C07K16/10 ,  A61P31/18

Abstract: Methods and compositions are provided that can be used to vaccinate against and treat HIV. Specifically contemplated are vaccine compositions and methods of using these compositions treat HIV in patients. Aspects of the disclosure relate to an anti-CD40 antibody-HIV antigen fusion protein comprising (i) an anti-CD40 heavy chain (HCD40)-HIV antigen (Ag) fusion protein comprising the formula: HCD40-Ag, wherein Ag is a polypeptide with at least 80% sequence identity to SEQ ID NO:1; and (ii) an anti-CD40 light chain (LCD40).